HealthInvest Partners AB
Latest statistics and disclosures from Atle Fund Management AB's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LLY, MRK, TMO, ONC, JNJ, and represent 28.51% of Atle Fund Management AB's stock portfolio.
- Added to shares of these 10 stocks: JNJ (+$12M), EW (+$8.3M), RVMD (+$7.8M), ISRG (+$6.5M), LLY (+$5.8M), MIRM (+$5.1M), INSM, CAH, TNGX, CELC.
- Started 4 new stock positions in EW, SYRE, JNJ, TNGX.
- Reduced shares in these 10 stocks: MRK (-$110M), CMPX (-$40M), CVS (-$32M), IONS (-$22M), BSX (-$15M), IDYA (-$8.5M), NAMS (-$5.9M), UFPT (-$5.1M), TMO, IRTC.
- Sold out of its positions in ACLX, AUTL, CRBP, UFPT.
- Atle Fund Management AB was a net seller of stock by $-191M.
- Atle Fund Management AB has $310M in assets under management (AUM), dropping by -1.20%.
- Central Index Key (CIK): 0001381843
Tip: Access up to 7 years of quarterly data
Positions held by HealthInvest Partners AB consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Atle Fund Management AB
Atle Fund Management AB holds 39 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Eli Lilly & Co. (LLY) | 8.7 | $27M | +27% | 40k | 675.83 |
|
| Merck & Co (MRK) | 7.4 | $23M | -82% | 34k | 676.96 |
|
| Thermo Fisher Scientific (TMO) | 4.7 | $14M | -23% | 23k | 628.64 |
|
| Beone Medicines Ltd- Sponsored Ads (ONC) | 3.9 | $12M | +3% | 42k | 290.94 |
|
| Johnson & Johnson (JNJ) | 3.9 | $12M | NEW | 92k | 129.29 |
|
| Bridgebio Pharma (BBIO) | 3.8 | $12M | -21% | 111k | 106.80 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 3.6 | $11M | 23k | 485.90 |
|
|
| Abbvie (ABBV) | 3.4 | $10M | 108k | 96.00 |
|
|
| Stryker Corporation (SYK) | 3.1 | $9.6M | 27k | 356.99 |
|
|
| Intuitive Surgical Com New (ISRG) | 3.0 | $9.4M | +217% | 71k | 133.30 |
|
| Ionis Pharmaceuticals (IONS) | 3.0 | $9.4M | -69% | 28k | 337.20 |
|
| Mirum Pharmaceuticals (MIRM) | 3.0 | $9.4M | +118% | 196k | 48.00 |
|
| CVS Caremark Corporation (CVS) | 3.0 | $9.3M | -77% | 24k | 389.82 |
|
| Revolution Medicines (RVMD) | 2.9 | $9.1M | +584% | 617k | 14.71 |
|
| Boston Scientific Corporation (BSX) | 2.9 | $8.8M | -62% | 40k | 218.74 |
|
| Amgen (AMGN) | 2.8 | $8.7M | 22k | 397.94 |
|
|
| Edwards Lifesciences (EW) | 2.7 | $8.3M | NEW | 107k | 77.61 |
|
| Alkermes SHS (ALKS) | 2.7 | $8.2M | 243k | 33.96 |
|
|
| Incyte Corporation (INCY) | 2.6 | $8.0M | -28% | 51k | 156.98 |
|
| Neurocrine Biosciences (NBIX) | 2.5 | $7.9M | -5% | 90k | 87.58 |
|
| Gilead Sciences (GILD) | 2.3 | $7.2M | -5% | 48k | 149.20 |
|
| Krystal Biotech (KRYS) | 2.2 | $6.8M | +11% | 38k | 180.79 |
|
| AmerisourceBergen (COR) | 2.1 | $6.6M | 24k | 281.35 |
|
|
| Irhythm Technologies (IRTC) | 2.0 | $6.3M | -40% | 22k | 280.43 |
|
| Insmed Com Par $.01 (INSM) | 1.9 | $6.0M | +249% | 97k | 61.12 |
|
| Newamsterdam Pharma Co Nv Ordinary Shares (NAMS) | 1.8 | $5.5M | -51% | 95k | 58.11 |
|
| Celcuity (CELC) | 1.7 | $5.1M | +237% | 141k | 36.39 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.5 | $4.8M | 32k | 151.43 |
|
|
| Cardinal Health (CAH) | 1.5 | $4.8M | +363% | 109k | 43.87 |
|
| Ideaya Biosciences (IDYA) | 1.3 | $4.0M | -68% | 31k | 128.85 |
|
| Tango Therapeutics (TNGX) | 1.2 | $3.6M | NEW | 30k | 121.33 |
|
| Spyre Therapeutics Com New (SYRE) | 1.1 | $3.5M | NEW | 63k | 55.56 |
|
| Disc Medicine (IRON) | 1.0 | $3.2M | +123% | 107k | 29.73 |
|
| Compass Therapeutics (CMPX) | 1.0 | $3.1M | -92% | 42k | 72.94 |
|
| UnitedHealth (UNH) | 0.9 | $2.8M | 15k | 189.43 |
|
|
| Dexcom Com New (DXCM) | 0.9 | $2.6M | +1371% | 584k | 4.52 |
|
| Bicara Therapeutics (BCAX) | 0.7 | $2.3M | +950% | 1.2M | 1.98 |
|
| Soleno Therapeutics (SLNO) | 0.7 | $2.2M | +43% | 90k | 24.48 |
|
| Pyxis Oncology Common Stock (PYXS) | 0.5 | $1.6M | -68% | 197k | 8.21 |
|
Past Filings by Atle Fund Management AB
SEC 13F filings are viewable for Atle Fund Management AB going back to 2013
- Atle Fund Management AB 2026 Q1 filed May 11, 2026
- Atle Fund Management AB 2025 Q4 filed Feb. 6, 2026
- Atle Fund Management AB 2025 Q3 filed Nov. 4, 2025
- Atle Fund Management AB 2025 Q2 filed July 14, 2025
- Atle Fund Management AB 2025 Q1 filed May 5, 2025
- HealthInvest Partners AB 2024 Q4 filed Feb. 4, 2025
- HealthInvest Partners AB 2024 Q3 filed Nov. 12, 2024
- HealthInvest Partners AB 2024 Q1 filed April 25, 2024
- HealthInvest Partners AB 2023 Q4 filed Jan. 30, 2024
- HealthInvest Partners AB 2022 Q4 filed Feb. 14, 2023
- HealthInvest Partners AB 2022 Q3 filed Oct. 21, 2022
- HealthInvest Partners AB 2022 Q2 filed July 8, 2022
- HealthInvest Partners AB 2022 Q1 filed May 5, 2022
- HealthInvest Partners AB 2021 Q4 filed Jan. 18, 2022
- HealthInvest Partners AB 2021 Q3 filed Nov. 8, 2021
- HealthInvest Partners AB 2021 Q2 filed Aug. 10, 2021